期刊
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
卷 21, 期 -, 页码 382-398出版社
CELL PRESS
DOI: 10.1016/j.omtm.2021.03.019
关键词
-
资金
- National Institute of Neurological Disorders and Stroke [P30-NS072030]
- NIH [P30-EY12196]
- National Institutes of Health [R01-DC017117, R01-DC016932]
- Waypoint Capital, Inc.
Research has shown that the AAV-S capsid has demonstrated efficient gene expression transduction in the inner ears of both mice and cynomolgus macaques, particularly showing promise in treating Usher syndrome type 3A.
Gene therapy strategies using adeno-associated virus (AAV) vectors to treat hereditary deafnesses have shown remarkable efficacy in some mouse models of hearing loss. Even so, there are few AAV capsids that transduce both inner and outer hair cells-the cells that express most deafness genes-and fewer still shown to transduce hair cells efficiently in primates. AAV capsids with robust transduction of inner and outer hair cells in primate cochlea will be needed for most clinical trials. Here, we test a capsid that we previously isolated from a random capsid library, AAV-S, for transduction in mouse and non-human primate inner ear. In both mice and cynomolgus macaques, AAV-S mediates highly efficient reporter gene expression in a variety of cochlear cells, including inner and outer hair cells, fibrocytes, and supporting cells. In a mouse model of Usher syndrome type 3A, AAV-S encoding CLRN1 robustly and durably rescues hearing. Overall, our data indicate that AAV-S is a promising candidate for therapeutic gene delivery to the human inner ear.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据